CORDIS
EU research results

CORDIS

English EN

Innovative anti-influenza drugs excluding viral escape

Objective

ANTIFLU is to develop innovative drugs against influenza virus infections based on a novel
concept that precludes the development of viral resistance and ensures efficacy against
upcoming pandemic influenza strains. Viral replication is known to depend on multiple host
factors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU will
aim at drugs interfering with host-response pathways. The concept of drugs targeting human
factors, established in treatment of other diseases, has yet not been sufficiently explored for
treatment of viral infections, although it bears compelling advantages over conventional
antiviral therapies: (i) the avoidance of viral escape mutants and (ii) the broad coverage
against unprecedented viral variants.
ANTIFLU aims to fully exploit this potent approach to fill critical gaps in our current treatment
and prevention options against seasonal and pandemic influenza virus infections. By building
upon an existing panel of potent human targets and firm knowledge derived from FP6 project
RIGHT, an interdisciplinary consortium will pursue the identification and validation of small
molecule ligands and inhibitory RNA molecules effective against influenza infection.
Promising modulators will form the basis to generate lead molecules that will be further
refined to yield clinically applicable therapeutics. Initial preclinical studies will aim at providing
proof of concept in animal models, safety and toxicology profiles. They will allow initiating
complete clinical trials immediately after the phase of FP7 support, thanks to the commitment
already taken by investors from the private sector. The consortium includes several SMEs,
internationally renowned research groups and clinical institutions with extensive experience
in anti-influenza treatment and clinical trials. An already agreed common exploitation model
will provide a smooth route to market and optimal use of the project results.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Address

Hofgartenstrasse 8
80539 Munich

Germany

Activity type

Other

EU Contribution

€ 1 448 954

Administrative Contact

Birgit Gieding (Ms.)

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

VICHEM CHEMIE KUTATO KFT

Hungary

EU Contribution

€ 621 500,20

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 548 576

LEAD DISCOVERY CENTER GMBH

Germany

EU Contribution

€ 1 629 860

INSTITUT PASTEUR

France

EU Contribution

€ 38 901

ARTTIC

France

EU Contribution

€ 344 000

MEDITOX S.R.O

Czechia

EU Contribution

€ 8 636

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 433 778

RiboTask ApS

Denmark

EU Contribution

€ 222 232,80

THE HEBREW UNIVERSITY OF JERUSALEM

Israel

EU Contribution

€ 289 560

FORSCHUNGSVERBUND BERLIN EV

Germany

EU Contribution

€ 414 000

Project information

Grant agreement ID: 259842

Status

Closed project

  • Start date

    1 June 2011

  • End date

    30 November 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 821 685,40

  • EU contribution

    € 5 999 998

Coordinated by:

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany